Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 dem...
Jun 5, 2025, 4:58 PM EDT - 7 weeks ago
May 23, 2025, 4:01 PM EDT - 2 months ago
May 9, 2025, 7:00 AM EDT - 2 months ago
Apr 3, 2025, 7:00 AM EDT - 4 months ago
Mar 27, 2025, 7:00 AM EDT - 4 months ago
Feb 26, 2025, 7:00 AM EST - 5 months ago
Feb 3, 2025, 10:00 AM EST - 6 months ago
Dec 12, 2024, 4:01 PM EST - 8 months ago
Nov 25, 2024, 7:00 AM EST - 8 months ago
Nov 7, 2024, 4:01 PM EST - 9 months ago
Nov 5, 2024, 7:00 AM EST - 9 months ago
Sep 11, 2024, 7:00 AM EDT - 11 months ago
Aug 12, 2024, 4:01 PM EDT - 1 year ago
Jun 5, 2024, 7:00 AM EDT - 1 year ago
May 13, 2024, 7:00 AM EDT - 1 year ago
May 6, 2024, 8:00 AM EDT - 1 year ago
Apr 11, 2024, 8:00 AM EDT - 1 year ago
Apr 8, 2024, 8:00 AM EDT - 1 year ago
Mar 30, 2024, 1:00 AM EDT - 1 year ago
MMA MNDR NTCL NTHI ROTR UBXG WAY
Mar 27, 2024, 6:55 PM EDT - 1 year ago
Mar 23, 2024, 12:20 AM EDT - 1 year ago
ALAB AUNA INTJ MNDR RDDT
Mar 12, 2024, 4:16 PM EDT - 1 year ago